Related Experiment Video
Updated: Sep 16, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Tirbanibulin 1% Ointment: Clinical Trial and Real-World Evidence on Efficacy, Tolerability, Safety, and
Abstract:
Actinic keratosis (AK) is a skin lesion that arises due to chronic sun exposure. Treatment of all AKs is recommended due to their risk of progressing to squamous cell carcinomas (SCCs). Many field-directed treatments for AKs involve burdensome treatment duration and frequency, compromising treatment compliance. Tirbanibulin 1% ointment is a first-in-class microtubule inhibitor that treats AKs by inhibiting Src kinase signaling and inducing pro-apoptotic effects. It is an approved treatment for field-directed therapy of AKs, administered once daily for 5 consecutive days. In addition to its convenience of use, tirbanibulin 1% ointment has demonstrated efficacy and safety in phases 1 to 3 clinical trials and favorable clinical outcomes in real-world clinical studies. This paper summarizes the comprehensive evidence from clinical trials and global clinical studies to guide clinical consideration of tirbanibulin 1% ointment in AK management.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Blinding
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

